Table 2.
Parameters | Overall survival | Univariate analysis | Multivariate analysis | ||||
---|---|---|---|---|---|---|---|
HR(95%CI) | p | HR(95%CI) | p | ||||
Primary treatment | 1-year OS | 3-year OS | 5-year OS | <0.001 | 0.001 | ||
SR | 87.4 | 73.3 | 61.5 | Reference | Reference | ||
RFA | 89.9 | 42.4 | 23.9 | 2.76 (1.61–4.73) | 3.26 (1.58–6.51) | ||
Race | 0.084 | 0.698 | |||||
White | 97.1 | 82.7 | 70.3 | Reference | Reference | ||
Black | 93.3 | 70.5 | 52.9 | 1.27 (0.44–3.68) | 1.24 (0.41–3.66) | ||
Other | 84.5 | 62.4 | 49.9 | 1.96 (1.01–3.80) | 2.12 (1.08–4.17) | ||
Gender | 0.880 | ||||||
Male | 86.4 | 66.5 | 56.1 | Reference | |||
Female | 89.7 | 68.7 | 53.7 | 0.96 (0.59–1.57) | |||
Year of diagnosis | 0.321 | ||||||
2004–2007 | 72.2 | 58.2 | 46.6 | Reference | |||
2008–2011 | 88.2 | 69.5 | 58.5 | 0.68 (0.40–1.18) | |||
2012–2014 | 85.7 | 77.2 | – | 0.58 (0.24–1.42) | |||
Age at diagnosis | 0.325 | ||||||
≤ 60 | 89.6 | 64.9 | 56.6 | Reference | |||
60–70 | 86.2 | 72.2 | 59.1 | 0.79 (0.43–1.44) | |||
>70 | 81.0 | 65.3 | 46.7 | 1.28 (0.71–2.28) | |||
Marital status | 0.082 | 0.803 | |||||
Married | 89.7 | 73.2 | 56.9 | Reference | Reference | ||
Divorced | 90.0 | 73.4 | 64.2 | 0.79 (0.33–1.88) | 0.89 (0.37–2.14) | ||
Single or widowed | 83.1 | 52.3 | 45.8 | 1.11 (0.54–2.24) | 1.07 (0.52–2.21) | ||
Tumor size (cm) | 0.032 | 0.046 | |||||
<3 | 85.6 | 75.4 | 62.9 | Reference | Reference | ||
3–5 | 89.6 | 61.2 | 48.4 | 1.60 (1.26–2.39) | 1.71 (1.01–2.90) | ||
Tumor grade | 0.051 | 0.295 | |||||
Grade I–II | 93.4 | 72.7 | 65.2 | Reference | Reference | ||
Grade III | 85.5 | 61.1 | 55.5 | 1.42 (0.73–2.76) | 1.42 (0.73–2.77) | ||
Unknown | 85.7 | 61.2 | 44.7 | 1.99 (1.15–3.45) | 1.25 (0.66–2.37) | ||
Radiation | 0.271 | ||||||
Yes | 83.3 | 75.0 | 66.7 | Reference | |||
No/unknown | 88.3 | 66.6 | 53.2 | 1.69 (0.61–4.65) | |||
Chemotherapy | 0.932 | ||||||
Yes | 80.3 | 63.8 | 59.5 | Reference | |||
No/unknown | 90.0 | 67.3 | 53.3 | 1.02 (0.56–1.85) |
HR, hazard ratio; CI, confidence interval; SR, surgical resection; RFA, radiofrequency ablation; OS, overall survival.